Apidra Solostar

Apidra Solostar is a rapid-acting insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes.

When used as a mealtime insulin, the dose of Apidra Solostar should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra Solostar given by subcutaneous injection should normally be used in regimens that include a longer-acting insulin.

Apidra Solostar is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients. Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles.

Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. As with all insulin preparations, the time course of Apidra action may vary by individual or at different times in the same individual and is dependent on many conditions, including the site of injection, local blood supply, or local temperature.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Apidra, which may be serious.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. All insulins, including Apidra Solostar, can cause hypokalemia, which if untreated, may be serious.

A reduction in the Apidra Solostar dose may be required in patients with renal or hepatic impairment.

Apidra Solostar for subcutaneous injection should not be mixed with insulins other than NPH. Do not mix Apidra Solostar with any insulin when used in the pump or for intravenous administration.

Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Observe for signs and symptoms of heart failure. Consider dosage reduction or discontinuation of TZD if heart failure occurs.

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Other adverse reactions commonly associated with Apidra Solostar include injection site reactions, lipodystrophy, pruritus, and rash.